Mood disorders in Huntington's disease: From behavior to cellular and molecular mechanisms

Frontiers in Behavioral Neuroscience

Volumn 8, Issue APR, 2014, Pages

  Pla, Patrick ^a,b,c   Orvoen, Sophie ^c   Saudou, Frédéric ^a,b   David, Denis J ^c   Humbert, Sandrine ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM U1005   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anxiety; BDNF; Depression; HPA axis; Huntingtin; Huntington's disease; Neurogenesis; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUSPIRONE; CITALOPRAM; HUNTINGTIN; NEUROLEPTIC AGENT; POLYGLUTAMINE; SERTRALINE; TETRABENAZINE;

AMINO TERMINAL SEQUENCE; ANXIETY; ANXIETY DISORDER; BEHAVIOR; BEHAVIOR DISORDER; CELL FUNCTION; CELL VACUOLE; CHOREA; DEGENERATIVE DISEASE; DEPRESSION; DRUG RESPONSE; EUKARYOTIC FLAGELLUM; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; MITOSIS; MOOD DISORDER; MOTOR CONTROL; MOTOR DYSFUNCTION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PREVALENCE; PROTEIN FUNCTION; REVIEW; RODENT MODEL; SEROTONINERGIC SYSTEM; SOMNOLENCE; TRANSCRIPTION REGULATION;

EID: 84899154969     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2014.00135     Document Type: Review

References (179)

1. Almqvist, E. W., Brinkman, R. R., Wiggins, S., Hayden, M. R., and The Canadian Collaborative Study of Predictive Testing. (2003). Psychological consequences and predictors of adverse events in the first 5 years after predictive testing of HD. Clin. Genet. 64, 300-309. doi: 10.1034/j.1399-0004.2003.00157.x
2. Alonso, M., Medina, J. H., and Pozzo-Miller, L. (2004). ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn. Mem. 11, 172-178. doi: 10.1101/lm.67804
3. Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., et al. (1997). Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856-860. doi: 10.1038/39885
4. Anderson, K. D., Alderson, R. F., Altar, C. A., DiStefano, P. S., Corcoran, T. L., Lindsay, R. M. and Wiegand, S. J. (1995). Differential distribution of exogenous BDNF, NGF and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity neurotrophin receptors. J. Comp. Neurol. 357, 296-317.
5. Antonijevic, I. A. (2006). Depressive disorders: is it time to endorse different pathophysiologies?Psychoneuroendocrinology 31, 1-15. doi: 10.1016/j.psyneuen.2005.04.004
6. Ardayfio, P., and Kim, K.-S. (2006). Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. Behav. Neurosci. 120, 249-256. doi: 10.1037/0735-7044.120.2.249
7. Autry, A. E., and Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64, 238-258. doi: 10.1124/pr.111.005108
8. Aziz, N. A., Pijl, H., Frölich, M., van der Graaf, A. W., Roelfsema F., and Roos, R. A. (2009). Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab. 94, 1223-1228. doi: 10.1210/jc.2008-2543
9. Ben M'Barek, K., Pla, P., Orvoen, S., Benstaali, C., Godin, J. D., Gardier, A. M., et al. (2013). Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis. J. Neurosci. 33, 8608-8620. doi: 10.1523/J.NEUROSCI.5110-12.2013
10. Bergami, M., Rimondini, R., Santi, S., Blum, R., Götz, M., and Canossa, M. (2008). Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc. Natl. Acad. Sci. U.S.A. 105, 15570-15575. doi: 10.1073/pnas.0803702105
11. Berrios, G. E., Wagle, A. C., Markova, I. S., Wagle, S. A., Ho, L. W., Rubinsztein, D. C., et al. (2001). Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res. 102, 217-225. doi: 10.1016/S0165-1781(01)00257-8
12. Berton, O., McClung, C. A., Dileone, R. J., Krishnan, V., Renthal, W., Russo, S. J., et al. (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864-868. doi: 10.1126/science.1120972
13. Björkqvist, M., Petersén, A., Bacos, K., Isaacs, J., Norlén, P., Gil, J., et al. (2006). Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 15, 1713-1721. doi: 10.1093/hmg/ddl094
14. Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Li, X.-J., and Li, S. (2009). Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 106, 22480-22485. doi: 10.1073/pnas.0911503106
15. Bruel-Jungerman, E., Veyrac, A., Dufour, F., Horwood, J., Laroche, S., and Davis, S. (2009). Inhibition of PI3K-Akt signaling blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in the dentate gyrus. PLoS ONE 4:e7901. doi: 10.1371/journal.pone.0007901
16. Cameron, H. A., and Gould, E. (1994). Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neurosci. 61, 203-209.
17. Caraceni, T., Calderini, G., Consolazione, A., Riva, E., Algeri, S., Girotti, F., et al. (1977). Biochemical aspects of Huntington's chorea. J. Neurol. Neurosurg. Psychiatry 40, 581-587. doi: 10.1136/jnnp.40.6.581
18. Castro, M. E., Pascual, J., Romon, T., and Pazos, A. (1998). 5-HT 1B receptor binding in degenerative movement disorders. Brain Res. 790, 323-328.
19. Cattaneo, E., Zuccato, C., and Tartari, M. (2005). Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930. doi: 10.1038/nrn1806
20. Cazorla, M., Jouvenceau, A., Rose, C., Guilloux, J.-P., Pilon, C., Dranovsky, A., et al. (2010). Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS ONE 5:e9777. doi: 10.1371/journal.pone.0009777
21. Chari, A., Quiraishi, S. H., and Jainer, A. K. (2003). Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. Pharmacopsychiatry 36, 41-43. doi: 10.1055/s-2003-38093
22. Chen, Z. Y., Jing, D., Bath, K. G., Ieraci, A., Khan, T., Siao, C. J., et al. (2006). Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314, 140-143. doi: 10.1126/science.1129663
23. Chiu, C.-T., Liu, G., Leeds, P., and Chuang, D.-M. (2011). Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36, 2406-2421. doi: 10.1038/npp.2011.128
24. Ciamei, A., and Morton, A. J. (2008). Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. Neurobiol. Learn. Mem. 89, 533-544. doi: 10.1016/j.nlm.2007.10.009
25. Colin, E., Zala, D., Liot, G., Rangone, H., Borrell-Pagès, M., Li, X.-J., et al. (2008). Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 27, 2124-2134. doi: 10.1038/emboj.2008.133
26. Craufurd, D., Thompson, J. C., and Snowden, J. S. (2001). Behavioral change in Huntington disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 219-226.
27. Curtis, M. A., Penney, E. B., Pearson, A. G., van Roon-Mom, W. M. C., Butterworth, N. J., Dragunow, M., et al. (2003). Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. U.S.A. 100, 9023-9027. doi: 10.1073/pnas.1532244100
28. David, D. J., Samuels, B. A., Rainer, Q., Wang, J., Marsteller, D., Mendez, I., et al. (2009). Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62, 479-493. doi: 10.1016/j.neuron.2009.04.017
29. Detke, M. J., Rickels, M., and Lucki, I. (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121, 66-72
30. Dietrich, P., Shanmugasundaram, R., Shuyu, E., and Dragatsis, I. (2009). Congenital hydrocephalus associated with abnormal subcommissural organ in mice lacking huntingtin in Wnt1 cell lineages. Hum. Mol. Genet. 18, 142-150. doi: 10.1093/hmg/ddn324
31. Donaldson, Z. R., Nautiyal, K. M., Ahmari, S. E., and Hen, R. (2013). Genetic approaches for understanding the role of serotonin receptors in mood and behavior. Curr. Opin. Neurobiol. 23, 399-406. doi: 10.1016/j.conb.2013.01.011
32. Dragatsis, I., Levine, M. S., and Zeitlin, S. (2000). Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300-306. doi: 10.1038/81593
33. Du, X., Leang, L., Mustafa, T., Renoir, T., Pang, T. Y., and Hannan, A. J. (2012). Environemental enrichement rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease. Transl. Psychiatry 2:e133. doi: 10.1038/tp.2012.58
34. Du, X., Pang, T. Y., and Hannan, A. J. (2013). A tale of two maladies? Pathogenesis of depression with and without the Huntington's Disease Gene Mutation. Front. Neurol. 4:81. doi: 10.3389/fneur.2013.00081
35. Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., and Mattson, M. P. (2003). Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. U.S.A. 100, 2911-2916. doi: 10.1073/pnas.0536856100
36. Duan, W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E., Ladenheim, B., et al. (2008). Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 30, 312-322. doi: 10.1016/j.nbd.2008.01.015
37. Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., and Stout, J. C. (2007). Psychiatric symptoms in Huntington's disease before diagnosis?: the predict-HD study. Biol. Psychiatry 62, 1341-1346. doi: 10.1016/j.biopsych.2006.11.034
38. Duman, R. S. (2004). Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 5, 11-25. doi: 10.1385/NMM:5:1:011
39. Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., et al. (1995). Inactivation of the Mouse Huntington's disease gene homolog Hdh. Science 269, 6182-6195.
40. Epping, E. A., Mills, J. A., Beglinger, L. J., Fiedorowicz, J. G., Craufurd, D., Smith, M. M., et al. (2013). Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J. Psychiatr. Res. 47, 1423-1431. doi: 10.1016/j.jpsychires.2013.05.026
41. Epping, E. A., and Paulsen, J. S. (2011). Depression in the early stages of Huntington disease. Neurodegener. Dis. Manag. 1, 407-414. doi: 10.2217/nmt.11.45
42. File, S. E., Mahal, A., Mangiarini, L., and Bates, G. P. (1998). Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res. 805, 234-240. doi: 10.1016/S0006-8993(98)00736-7
43. Folstein, S. E., Chase, G. A., Wahl, W. E., McDonnell, A. M., and Folstein, M. F. (1987). HD in Maryland?: clinical aspects of racial variation. Am. J. Hum. Genet. 41, 168-179.
44. Frank, S. (2010). Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington's disease. Neuropsychiatr. Dis. Treat. 6, 657-665. doi: 10.2147/NDT.S6430
45. Fuss, J., Ben Abdallah, N. M. B., Hensley, F. W., Weber, K.-J., Hellweg, R., and Gass, P. (2010). Deletion of running-induced hippocampal neurogenesis by irradiation prevents development of an anxious phenotype in mice. PLoS ONE 5:e12769. doi: 10.1371/journal.pone.0012769
46. Gafni, J., Hermel, E., Young, J. E., Wellington, C. L., Hayden, M. R., and Ellerby, L. M. (2004). Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279, 20211-20220. doi: 10.1074/jbc.M401267200
47. Gauthier, L. R., Charrin, C., Dompierre, J. P., Borrell-Pagès, M., Cordelières, F. P., De Mey, J., et al. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138. doi: 10.1016/j.cell.2004.06.018
48. Gil, J. M. A. C., Mohapel, P., Araújo, I. M., Popovic, N., Li, J.-Y., Brundin, P., et al. (2005). Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis. 20, 744-751. doi: 10.1016/j.nbd.2005.05.006
49. Ginés, S., Bosch, M., Marco, S., Gavaldà, N., Díaz-Hernández, M., Lucas, J. J., et al. (2006). Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci. 23, 649-658. doi: 10.1111/j.1460-9568.2006.04590.x
50. Ginés, S., Paoletti, P., and Alberch, J. (2010). Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J. Biol. Chem. 285, 21537-21548. doi: 10.1074/jbc.M109.084202
51. Gomez-Palacio-Schjetnan, A., and Escobar, M. L. (2013). Neurotrophins and synaptic plasticity. Curr. Top. Behav. Neurosci. 15, 117-136. doi: 10.1007/7854_2012_231
52. Gourley, S. L., Kiraly, D. D., Howell, J. L., Olausson, P., and Taylor, J. R. (2008). Acute hippocampal brain-derived neurotrophic factor restores motivational and forced swim performance after corticosterone. Biol. Psychiatry 64, 884-890. doi: 10.1016/j.biopsych.2008.06.016
53. Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., et al. (2006). Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125, 1179-1191. doi: 10.1016/j.cell.2006.04.026
54. Gray, M., Shirasaki, D. I., Cepeda, C., André, V. M., Wilburn, B., Lu, X.-H., et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195. doi: 10.1523/JNEUROSCI.0857-08.2008
55. Gross, C., Santarelli, L., Brunner, D., Zhuang, X., and Hen, R. (2000). Altered fear circuits in 5-HT(1A) receptor KO mice. Biol. Psychiatry 48, 1157-1163. doi: 10.1016/S0006-3223(00)01041-6
56. Grote, H. E., Bull, N. D., Howard, M. L., van Dellen, A., Blakemore, C., Bartlett, P. F., et al. (2005). Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci. 22, 2081-2088. doi: 10.1111/j.1460-9568.2005.04365.x
57. Hackam, S., Singaraja, R., Wellington, C. L., Metzler, M., McCutcheon, K., Zhang, T., et al. (1998). The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141, 1097-1105.
58. Heng, M. Y., Detloff, P. J., and Albin, R. L. (2008). Rodent genetic models of Huntington disease. Neurobiol. Dis. 32, 1-9. doi: 10.1016/j.nbd.2008.06.005
59. Heuser, I. J., Chase, T. N., and Mouradian, M. M. (1991). The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol. Psychiatry 30, 943-952.
60. Hickey, M. A., Gallant, K., Gross, G. G., Levine, M. S., and Chesselet, M.-F. (2005). Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 20, 1-11. doi: 10.1016/j.nbd.2005.01.024
61. Hickey, M. A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M. S., et al. (2008). Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157, 280-295. doi: 10.1016/j.neuroscience.2008.08.041
62. Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., et al. (1999). A YAC mouse model for huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192.
63. Holmes, A., Yang, R. J., Murphy, D. L., and Crawley, J. N. (2002). Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27, 914-923. doi: 10.1016/S0893-133X(02)00374-3
64. Hu, Y., and Russek, S. J. (2008). BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J. Neurochem. 105, 1-17. doi: 10.1111/j.1471-4159.2008.05237.x
65. Humbert, S., Bryson, E. A., Cordelières, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., et al. (2002). The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell. 2, 831-837. doi: 10.1016/S1534-5807(02)00188-0
66. Jones, M. D., and Lucki, I. (2005). Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. Neuropsychopharmacology 30, 1039-1047. doi: 10.1038/sj.npp.1300664
67. Jongen, P. J., Reiner, W. O., and Gabreëls, F. J. (1980). Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic-rigid form. Clin. Neurol. Neurosurg. 82, 251-261
68. Julien, C. L., Thompson, J. C., Wild, S., Yardumian, P., Snowden, J. S., Turner, G., et al. (2007). Psychiatric disorders in preclinical Huntington's disease. J. Neurol. Neurosurg. Psychiatry 78, 939-943. doi: 10.1136/jnnp.2006.103309
69. Karishma, K. K., and Herbert, J. (2002). Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur. J. Neurosci. 16, 445-453. doi: 10.1046/j.1460-9568.2002.02099.x
70. Kingma, E. M., van Duijn, E., Timman, R., van der Mast, R. C., and Roos, R. A. C. (2008). Behavioral problems in Huntington's disease using the Problem Behaviors Assessment. Gen. Hosp. Psychiatry 30, 155-161. doi: 10.1016/j.genhosppsych.2007.11.005
71. Klempin, F., Babu, H., De Pietri Tonelli, D., Alarcon, E., Fabel, K., and Kempermann, G. (2010). Oppositional effects of serotonin receptors 5-HT1a, 2, and 2c in the regulation of adult hippocampal neurogenesis. Front. Mol. Neurosci. 3:14. doi: 10.3389/fnmol.2010.00014
72. Klivenyi, P., Bende, Z., Hartai, Z., Penke, Z., Nemeth, H., Toldi, J., et al. (2006). Behaviour changes in a transgenic model of Huntington's disease. Behav. Brain Res. 169, 137-141. doi: 10.1016/j.bbr.2006.01.003
73. Kohl, Z., Kandasamy, M., Winner, B., Aigner, R., Gross, C., Couillard-Despres, S., et al. (2007). Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Brain Res. 1155, 24-33. doi: 10.1016/j.brainres.2007.04.039
74. Kornstein, S. G., Schatzberg, F., Thase, M. E., Yonkers, K., McCullough, J. P., Keitner, G. I., et al. (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry 157, 1445-1452. doi: 10.1176/appi.ajp.157.9.1445
75. Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., et al. (2007). Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391-404. doi: 10.1016/j.cell.2007.09.018
76. Krogias, C., Strassburger, K., Eyding, J., Gold, R., Norra, C., Juckel, G., et al. (2011). Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J. Psychiatry Neurosci. 36, 187-194. doi: 10.1503/jpn.100067
77. Kupfer, D. J., Frank, E., and Phillips, M. L. (2012). Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379, 1045-1055. doi: 10.1016/S0140-6736(11)60602-8
78. Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., et al. (2010). Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285, 8808-8823. doi: 10.1074/jbc.M109.075028
79. Lazic, S. E., Grote, H. E., Armstrong, R. J. E., Blakemore, C., Hannan, A. J., van Dellen, A., et al. (2004). Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport 15, 811-813.
80. Lazic, S. E., Grote, H. E., Blakemore, C., Hannan, A. J., van Dellen, A., Phillips, W., et al. (2006). Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 23, 1829-1838. doi: 10.1111/j.1460-9568.2006.04715.x
81. Lazo, O. M., Gonzalez, A., Ascano, M., Kuruvilla, R., and Couve, A. (2013). BDNF regulates Rab11-mediated recycling endosome dynamics to induce dendritic branching. J. Neurosci. 33, 6112-6122. doi: 10.1523/JNEUROSCI.4630-12.2013.BDNF
82. Leblhuber, F., Peichl, M., Neubauer, C., Reisecker, F., Steinparz, F. X., Windhager, E., et al. (1995). Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J. Neurol. Sci. 132, 76-79.
83. Lee, J., Duan, W., and Mattson, M. P. (2002). Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 82, 1367-1375. doi: 10.1046/j.1471-4159.2002.01085.x
84. Levy, M. L., Cummings, J. L., Fairbanks, L. A., Masterman, D., Miller, B. L., Craig, A. H., et al. (1998). Apathy is not depression. J. Neuropsy. Clin. Neurosci. 10, 314-319.
85. Li, S., Gutekunst, C., Hersch, S. M., and Li, X. (1998). Interaction of Huntingtin-Associated Protein with Dynactin P150 Glued. J. Neurosci. 18, 1261-1269.
86. Li, X., Valencia, A., Sapp, E., Masso, N., Alexander, J., Reeves, P., et al. (2010). Aberrant Rab11-Dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's Disease. J. Neurosci. 30, 4552-4561. doi: 10.1523/JNEUROSCI.5865-09.2010
87. Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., et al. (2008). TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59, 399-412. doi: 10.1016/j.neuron.2008.06.023
88. Liot, G., Zala, D., Pla, P., Mottet, G., Piel, M., and Saudou, F. (2013). Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci. 33, 6298-6309. doi: 10.1523/JNEUROSCI.2033-12.2013
89. Lira, A., Zhou, M., Castanon, N., Ansorge, M. S., Gordon, J. A., Francis, J. H., et al. (2003). Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960-971. doi: 10.1016/S0006-3223(03)00696-6
90. Luellen, B. A., Bianco, L. E., Schneider, L. M., and Andrews, A. M. (2007). Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes. Brain. Behav. 6, 482-490. doi: 10.1111/j.1601-183X.2006.00279.x
91. Lyons, W. E., Mamounas, L. A., Ricaurte, G. A., Coppola, V., Reid, S. W., Bora, S. H., et al. (1999). Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl. Acad. Sci. U.S.A. 96, 15239-15344.
92. Madhav, T. R., Pei, Q., and Zetterström, T. S. (2001). Serotonergic cells of the rat raphe nuclei express mRNA of tyrosine kinase B (trkB), the high-affinity receptor for brain derived neurotrophic factor (BDNF). Mol. Brain Res. 93, 56-63. doi: 10.1016/S0169-328X(01)00183-8
93. Malberg, J. E., and Blendy, J. A. (2005). Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci. 26, 631-638. doi: 10.1016/j.tips.2005.10.005
94. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
95. Marshall, J., White, K., Weaver, M., Flury Wetherill, L., Hui, S., Stout, J. C., et al. (2007). Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch. Neurol. 64, 116-121. doi: 10.1001/archneur.64.1.116
96. Mayorga, A. J., Dalvi, A., Page, M. E., Zimov-Levinson, S., and Hen, R. (2001). Antidepressant-Like Behavioral Effects in 5HTR1A and 5HTR1B mutant mice. J. Pharmacol. Exp. Ther. 298, 1101-1107.
97. McGuire, J. R., Rong, J., Li, S.-H., and Li, X.-J. (2006). Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J. Biol. Chem. 281, 3552-3559. doi: 10.1074/jbc.M509806200
98. Menalled, L., El-Khodor, B. F., Patry, M., Suárez-Fariñas, M., Orenstein, S. J., Zahasky, B., et al. (2009). Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319-336. doi: 10.1016/j.nbd.2009.05.007
99. Mendez-David, I., David, D. J., Darcet, F., Wu, V. W., Kerdine-Romer, S., Gardier, A. M., et al. (2014). Rapid anxiolytic effect of 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 39, 1366-1378. doi: 10.1038/npp.2013.332
100. Mestre, T. A. and Ferreira, J. J. (2012). An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat. Disord. 18, 316-320. doi: 10.1016/j.parkreldis.2011.10.021
101. Miller, B. H., Schultz, L. E., Gulati, A., Su, A. I., and Pletcher, M. T. (2010). Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety. PLoS ONE 5:e14458. doi: 10.1371/journal.pone.0014458
102. Milnerwood, A. J., and Raymond, L. A. (2007). Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol. 585, 817-831. doi: 10.1113/jphysiol.2007.142448
103. Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., et al. (2004). Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. U.S.A. 101, 10827-10832. doi: 10.1073/pnas.0402141101
104. Monteggia, L. M., Luikart, B., Barrot, M., Theobold, D., Malkovska, I., Nef, S., et al. (2007). Brain-Derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatry 187-197. doi: 10.1016/j.biopsych.2006.03.021
105. Mozhui, K., Karlsson, R.-M., Kash, T. L., Ihne, J., Norcross, M., Patel, S., et al. (2010). Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J. Neurosci. 30, 5357-5367. doi: 10.1523/JNEUROSCI.5017-09.2010
106. Murray, F., Smith, D. W., and Hutson, P. H. (2008). Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviors in mice. Eur. J. Pharmacol. 583, 115-127. doi: 10.1016/j.ejphar.2008.01.014
107. Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, J. M., Richman, J., Zeisler, A., et al. (1995). Targeted disruption of Huntington's disease results in embryonic lethality and behavioral and morphological consequences in heterozygotes. Cell 81, 811-823.
108. Naver, B., Stub, C., Møller, M., Fenger, K., Hansen, A. K., Hasholt, L., et al. (2003). Molecular and behavioral analysis of the r6/1 huntington's disease transgenic mouse. Neuroscience 122, 1049-1057. doi: 10.1016/j.neuroscience.2003.08.053
109. Nestler, E. J., Barrot, M., Dileone, R. J., Eisch, A. J., Gold, S. J., and Monteggia, L. M. (2002). Neurobiology of depression review. Neuron 34, 13-25. doi: 10.1016/S0896-6273(02)00653-0
110. Nithianantharajah, J., Barkus, C., Murphy, M., and Hannan, A. J. (2008). Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 29, 490-504. doi: 10.1016/j.nbd.2007.11.006
111. Novak, M. J. U., and Tabrizi, S. J. (2011). Huntington's disease: clinical presentation and treatment. Int. Rev. Neurobiol. 98, 297-323. doi: 10.1016/B978-0-12-381328-2.00013-4
112. Orvoen, S., Pla, P., Gardier, A. M., Saudou, F., and David, D. J. (2012). Huntington's disease knock-in male mice show specific anxiety-like behavior and altered neuronal maturation. Neurosci. Lett. 507, 127-132. doi: 10.1016/j.neulet.2011.11.063
113. Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G., and Lucki, I. (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147, 162-167
114. Pang, T. Y. C., Stam, N. C., Nithianantharajah, J., Howard, M. L., and Hannan, A. J. (2006). Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 141, 569-584. doi: 10.1016/j.neuroscience.2006.04.013
115. Pang, T. Y., Du, X., Zajac, M. S., Howard, M. L., and Hannan, A. J. (2009). Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 18, 753-766. doi: 10.1093/hmg/ddn385
116. Paulsen, J. S. (2011). Cognitive impairment in huntington disease: diagnosis and treatment. Curr. Neurol. Neurosci. Rep. 11, 474-483. doi: 10.1007/s11910-011-0215-x
117. Paulsen, J. S., Nehl, C., Hoth, K. F., Kanz, J. E., Benjamin, M., Conybeare, R., et al. (2005). Depression and Stages of Huntington's Disease. J. Neuropsychiatr. 496-502. doi: 10.1176/appi.neuropsych.17.4.496
118. Peinemann, A., Schuller, S., Pohl, C., Jahn, T., Weindl, A., and Kassubek, J. (2005). Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 239, 11-19. doi: 10.1016/j.jns.2005.07.007
119. Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C. A., et al. (2008). The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 210, 154-163. doi: 10.1016/j.expneurol.2007.10.015
120. Phillips, W., Morton, A. J., and Barker, R. A. (2005). Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci. 25, 11564-11576. doi: 10.1523/JNEUROSCI.3796-05.2005
121. Pineda, J. R., Canals, J. M., Bosch, M., Adell, A., Mengod, G., Artigas, F., et al. (2005). Brain-derived neurotrophic factor modulate dopaminergic deficits in a transgenic mouse model of Huntington's disease. J. Neurochem. 93, 1057-1068. doi: 10.1111/j.1471-4159.2005.03047.x
122. Pla, P., Orvoen, S., Benstaali, C., Dodier, S., Gardier, A. M., David, D. J., et al. (2013). Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse. PLoS ONE8:e73902. doi: 10.1371/journal.pone.0073902
123. Pouladi, M. A., Graham, R. K., Karasinska, J. M., Xie, Y., Santos, R. D., Petersén, A., et al. (2009). Prevention of depressive behavior in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132, 919-932. doi: 10.1093/brain/awp006
124. Pouladi, M. A., Morton, A. J., and Hayden, M. R. (2013). Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci. 14, 708-721. doi: 10.1038/nrn3570
125. Pouladi, M. A., Stanek, L. M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y., et al. (2012). Marked differences in neurochemistry and aggregates despite similar behavioral and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 21, 2219-2232. doi: 10.1093/hmg/dds037
126. Quesseveur, G., David, D. J., Gaillard, M. C., Pla, P., Wu, M. V., Nguyen, H. T., et al. (2013). BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl. Psychiatry 3, e253. doi: 10.1038/tp.2013.30
127. Rainnie, D. G. (1999). Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J. Neurophysiol. 82, 69-85.
128. Rangone, H., Poizat, G., Troncoso, J., Ross, C. A., MacDonald, M. E., Saudou, F., et al. (2004). The serum and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 19, 273-279. doi: 10.1111/j.0953-816X.2003.03131.x
129. Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., et al. (2007). Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 32, 2152-2162. doi: 10.1038/sj.npp.1301345
130. Reedeker, W., van der Mast, R. C., Giltay, E. J., Kooistra, T. A., Roos, R. A., and van Duijn, E. (2012). Psychiatric disorders in Huntington's disease: a 2-year follow-up study. Psychosomatics 53, 220-229. doi: 10.1016/j.psym.2011.12.010
131. Renoir, T., Pang, T. Y. C., Zajac, M. S., Chan, G., Du, X., Leang, L., et al. (2012). Treatment of depressive-like behavior in Huntington's disease mice by chronic sertraline and exercise. Br. J. Pharmacol. 165, 1375-1389. doi: 10.1111/j.1476-5381.2011.01567.x
132. Renoir, T., Zajac, M. S., Du, X., Pang, T. Y., Leang, L., Chevarin, C., et al. (2011). Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's Disease and depression. PLoS ONE 6:e22133. doi: 10.1371/journal.pone.0022133
133. Huntington Collaborative Research Group (1993). A novel gene containing a trinucleotide that is expanded and unstable on huntington's disease chromosomes. Cell 72, 971-983.
134. Richards, G., Messer, J., Waldvogel, H. J., Gibbons, H. M., Dragunow, M., Faull, R. L. M., et al. (2011). Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography. Brain Res. 1370, 204-214. doi: 10.1016/j.brainres.2010.11.020
135. Rong, J., Li, S., Sheng, G., Wu, M., Coblitz, B., Li, M., et al. (2007). 14-3-3 protein interacts with Huntingtin-associated protein 1 and regulates its trafficking. J. Biol. Chem. 282, 4748-4756. doi: 10.1074/jbc.M609057200
136. Rosenblatt, A. (2007). Neuropsychiatry of HD. Dialogues Clin. Neurosci. 9, 191-197.
137. Rowe, K. C., Paulsen, J. S., Langbehn, D. R., Wang, C., Mills, J., Beglinger, L. J., et al. (2012). Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 196, 309-314. doi: 10.1016/j.psychres.2011.09.005
138. Rubinow, D. R., Roca, C. A., Schmidt, P. J., Danaceau, M. A., Putnam, K., Cizza, G., et al. (2005). Testosterone suppression of CRH-stimulated cortisol in men. Neuropsychopharmacology 30, 1906-1912. doi: 10.1038/sj.npp.1300742
139. Rudolph, U., and Möhler, H. (2014). GABAA receptor subtypes: therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 54, 483-507. doi: 10.1146/annurev-pharmtox-011613-135947
140. Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., Macdonald, E., et al. (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23, 349-357.
141. Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., and Castrén, E. (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 25, 1089-1094. doi: 10.1523/JNEUROSCI.3741-04.2005
142. Samuels, B., and Hen, R. (2011). Neurogenesis and affective disorders. Eur. J. Neurosci. 33, 1152-1159. doi: 10.1111/j.1460-9568.2011.07614.x
143. Saydoff, J. A., Garcia, R. A. G., Browne, S. E., Liu, L., Sheng, J., Brenneman, D., Hu, Z., et al. (2006). Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol. Dis. 24, 455-465. doi: 10.1016/j.nbd.2006.08.011
144. Schilling, G., Becher, M. W., Sharp, A. H., Jinnah, H. A., Duan, K., Kotzuk, J. A., et al. (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407. doi: 10.1093/hmg/8.3.397
145. Seo, H., and Sonntag, K. C., Isacson, O. (2004). Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 56, 319-328. doi: 10.1002/ana.20207
146. Shirbin, C. A., Chua, P., Churchyard, A., Lowndes, G., Hannan, A. J., Pang, T. Y., et al. (2013). Cortisol and depression in pre-diagnosed and early stage Huntington's disease. Psychoneuroendocrinology 38, 2439-2447. doi: 10.1016/j.psyneuen.2012.10.020
147. Simmons, D. A., Rex, C. S., Palmer, L., Pandyarajan, V., Fedulov, V., Gall, C. M., et al. (2009). Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc. Natl. Acad. Sci. U.S.A. 106, 4906-4911. doi: 10.1073/pnas.0811228106
148. Simpson, J. M., Gil-Mohapel, J., Pouladi, M. A., Ghilan, M., Xie, Y., Hayden, M. R., et al. (2011). Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis. 41, 249-260. doi: 10.1016/j.nbd.2010.09.012
149. Smith, M. M., Mills, J. A., Epping, E. A., Westervelt, H., Paulsen, J. S., and PREDICT-HD Investigators of the Huntington Study Group. (2012). Depressive symptom severity is related to poorer cognitive performance in Prodromal Huntington Disease. Neuropsychology 26, 664-669. doi: 10.1037/a0029218
150. Steward, L. J., Bufton, K. E., Hopkins, P. C., Davies, W. E., and Barnes, N. M. (1993). Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease. Eur. J. Pharmacol. 242, 137-143.
151. Strand, A. D., Baguet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C., et al. (2007). Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 27, 11758-11768. doi: 10.1523/JNEUROSCI.2461-07.2007
152. Sullivan, F. R., Bird, E. D., Alpay, M., and Cha, J. H. (2001). Remotivation therapy and Huntington's disease. J. Neurosci. Nurs. 33, 136-142.
153. Thompson, J. C., Harris, J., Sollom, A. C., Stopford, C. L., Howard, E., Snowden, J. S., et al. (2012). Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 24, 53-60. doi: 10.1176/appi.neuropsych.11030057
154. Trivedi, M. H., and Greer, T. L. (2014). Cognitive dysfunction in unipolar depression: implications for treatment. J. Affect. Dis. 152, 19-27. doi: 10.1016/j.jad.2013.09.012
155. Twelvetrees, A. E., Yuen, E. Y., Arancibia-Carcamo, I. L., MacAskill, A. F., Rostaing, P., Lumb, M. J., et al. (2010). Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 65, 53-65. doi: 10.1016/j.neuron.2009.12.007
156. Tyler, W. J., and Pozzo-Miller, L. (2003). Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J. Physiol. 553, 497-509. doi: 10.1113/jphysiol.2003.052639
157. Van Duijn, E., Kingma, E. M., Timman, R., Zitman, F. G., Tibben, A., Roos, R. A. C., et al. (2008). Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first degree relatives. J. Clin. Psychiatry 69, 1804-1810.
158. Van Duijn, E., Selis, M. A., Giltay, E. J., Zitman, F. G., Roos, R. A. C., van Pelt, H., et al. (2010). Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls. Brain Res. Bull. 83, 232-237. doi: 10.1016/j.brainresbull.2010.08.006
159. Von Bohlen und Halbach, O., Krause, S., Medina, D., Sciarretta, C., Minichiello, L., and Unsicker, K. (2006). Regional-and age-dependent reduction in trkB receptor expression in the hippocampus is associated with altered spine morphologies. Biol. Psychiatry 59, 793-800. doi: 10.1016/j.biopsych.2005.08.025
160. Von Bohlen und Halbach, O., Minichiello, L., and Unsicker, K. (2008). TrkB but not trkC receptors are necessary for postnatal maintenance of hippocampal spines. Neurobiol. Aging 29, 1247-1255. doi: 10.1016/j.neurobiolaging.2007.02.028
161. Waeber, C., and Palacios, J. M. (1989). Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study. Neuroscience32, 337-347.
162. Walker, F. O. (2007). Huntington's disease. Lancet 369, 218-228. doi: 10.1016/S0140-6736(07)60111-1
163. Walker, T. L., Turnbull, G. W., Mackay, E. W., Hannan, A. J., and Bartlett, P. F. (2011). The latent stem cell population is retained in the hippocampus of transgenic Huntington's disease mice but not wild-type mice. PLoS ONE 6:e18153. doi: 10.1371/journal.pone.0018153
164. Wang, H., Chen, X., Li, Y., Tang, T.-S., and Bezprozvanny, I. (2010). Tetrabenazine is neuroprotective in Huntington's disease mice. Mol. Neurodegener. 5, 18. doi: 10.1186/1750-1326-5-18
165. Wong, E. H., Reynolds, G. P., Bonhaus, D. W., Hsu, S., and Eglen, R. M. (1996). Characterization of 3HGR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behav. Brain Res. 73, 249-252.
166. Xia, L., Deloménie, C., David, I., Rainer, Q., Marouard, M., Delacroix, H., et al. (2012). Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT 1A and 5-HT 1B receptors disruption in mice. Neurosci. Lett. 521, 20-25. doi: 10.1016/j.neulet.2012.05.046
167. Xie, Y., Hayden, M. R., and Xu, B. (2010). BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 30, 14708-14718. doi: 10.1523/JNEUROSCI.1637-10.2010
168. Yohrling, G. J. IV., Jiang, G. C. T., DeJohn, M. M., Robertson, D. J., Vrana, K. E., and Cha, J. H. J. (2002). Inhibition of tryptophan hydroxylase activity and decreased 5-HT 1A receptor binding in a mouse model of Huntington's disease. J. Neurochem. 82, 1416-1423. doi: 10.1046/j.1471-4159.2002.01084.x
169. Young, A. B., Greenamyre, J. T., Hollingsworth, Z., Albin, R., D'Amato, C., Shoulson, I. R. A., et al. (1988). NMDA Receptor Losses in Putamen from Patients with Huntington's Disease. Science 241, 981-983.
170. Yu, H., and Chen, Z. (2011). The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 32, 3-11. doi: 10.1038/aps.2010.184
171. Yuen, E. Y., Wei, J., Zhong, P., and Yan, Z. (2012). Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease. Neurobiol. Dis. 46, 497-502. doi: 10.1016/j.nbd.2012.02.015
172. Zajac, M. S., Pang, T. Y. C., Wong, N., Weinrich, B., Leang, L. S. K., Craig, J. M., et al. (2010). Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 20, 621-636. doi: 10.1002/hipo.20658
173. Zala, D., Colin, E., Rangone, H., Liot, G., Humbert, S., and Saudou, F. (2008). Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet. 17, 3837-3846. doi: 10.1093/hmg/ddn281
174. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11, 155-163.
175. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498. doi: 10.1126/science.1059581
176. Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., et al. (2005). Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52, 133-139. doi: 10.1016/j.phrs.2005.01.001
177. Zuccato, C., Marullo, M., Conforti, P., MacDonald, M. E., Tartari, M., and Cattaneo, E. (2008). Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18, 225-238. doi: 10.1111/j.1750-3639.2007.00111.x
178. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83. doi: 10.1038/ng1219
179. Zuccato, C., Valenza, M., and Cattaneo, E. (2010). Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease. Physiol. Rev. 905-981. doi: 10.1152/physrev.00041.2009